Additionally, monitoring TNF-α alone is insufficient – other cytokines such as IL-6,[7] and immune cell populations, including lymphocyte subsets, may also play a role in the pathogenesis of rituximab-associated ILD and warrant further investigation. Here, IL6 is linked to interstitial lung disease.